-Omics and Cancer Biomarkers: Link to the Biological Truth or Bear the Consequences

Liotta, Lance A.; Petricoin, Emanuel F.

doi:10.1158/1055-9965.epi-12-0635

Cited by 19 publications

(17 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Generating a list of activated proteins and pathways found in a diseased sample may not have any clinical impact if the biology of the tumor is not known or ignored. Confidence in biomarker applications for early detection, high-risk screening, recurrence monitoring, or individualized therapy could significantly increase if there is an understanding of the biological and biochemical effects of existing overexpressing and/or under-expressing proteins in an patient’s tumor [74]. …”

Section: Discussionmentioning

confidence: 99%

“…Although, chemical and protein-based phosphatase inhibitors are used to prevent substrate dephosphorylation by phosphatases in the absence of kinase activity, there is still room for any remaining active kinases to be affected [72, 73]. The balance between kinases and phosphatases is a major source of false positives and false negatives in the field of biomarker discovery [74]. Tissue samples for RPPA protein pathway profiling require stabilization, or preservation, of the kinases and phophoproteins immediately post tissue procurement to maintain the fidelity of data generated by protein analysis.…”

Section: Tissue Microenvironment: a True Representation Of Diseasementioning

confidence: 99%

See 1 more Smart Citation

Reverse Phase Protein Arrays: Mapping the Path Towards Personalized Medicine

Gallagher

Espina

2014

Mol Diagn Ther

View full text Add to dashboard Cite

Reverse phase protein array (RPPA) technology evolved from the advent of miniaturized immunoassays and gene microarray technology. Reverse phase protein arrays provide either a low throughput or high throughput methodology for quantifying proteins and their post-translationally modified forms in both cellular and non-cellular samples. As the demand for patient tailored therapies increases so does the need for precise and sensitive technology to accurately profile the molecular circuitry driving an individual patient’s disease. RPPAs are currently utilized in clinical trials for profiling and comparing the functional state of protein signaling pathways, either temporally within tumors, between patients, or within the same patients before/after treatment. RPPAs are generally employed for quantifying large numbers of samples on one array, under identical experimental conditions. However, the goal of personalized cancer medicine is to design therapies based on the molecular portrait of a patient’s tumor, which in turn result in more efficacious treatments with less toxicity. Therefore, RPPAs are also being validated for low throughput assays of individual patient samples. This review explores reverse phase protein array technology in the cancer research field, concentrating on its role as a fundamental tool for deciphering protein signaling networks and its emerging role in personalized medicine.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Tissue Microenvironment: a True Representation Of Diseasementioning

confidence: 99%

Reverse Phase Protein Arrays: Mapping the Path Towards Personalized Medicine

Gallagher

Espina

2014

Mol Diagn Ther

View full text Add to dashboard Cite

show abstract

“…Recently, with the merging of "omic" technologies such as genomics, proteomics, metabolomics, transcriptomics, etc., a great advancement has been achieved in the field of cancer biology with better understanding of carcinogenesis, cancer progression, metastasis, and target therapy [35]. Microarray, mass spectrometry, and sequencing techniques provide evolutionary era for promising cancer biomarkers [36].…”

Section: "Omics" and Promising Biomarkers In Breast Cancermentioning

confidence: 99%

Molecular Fingerprints and Biomarkers of Breast Cancer

Kamel¹,

Al-Amodi²,

Elmoneim³

2017

Breast Cancer - From Biology to Medicine

View full text Add to dashboard Cite

Substantial progress has been made over the past three decades in understanding breast cancer (BC) molecular biology, genomics, and targeted therapy. The recent comprehensive molecular and pathological diversity observed in BC patients indicates that BC is not a homogeneous disease; It may be appropriately defined as a myriad of diseases. The explosion of molecular information in the past 10 years has led to a better understanding of the biologic diversity of breast cancers (BCs), and clues to the different etiologic pathways to BC development. It will be useful to study the epigenetics of BC cells and define the mechanisms of both genetic and epigenetic driving alterations beside the mutations. Identifying the oncogenes and tumor suppressor genes is the purpose cancer diagnostics and therapeutics. Oncogenes as well as novel ones involved in the significantly altered regions would enable researchers to identify new causes and molecular pathways that may be targeted at BC treatment. Our main goal is to provide comprehensive understanding of underlying molecular mechanisms and hallmarks of BC, focusing on the identification of fingerprints and novel molecular targets that will greatly improve the cancer predictive, prognostic, and diagnostic biomarkers and, in addition, the possible targets for novel therapies.

show abstract

“…By understanding the molecular mechanisms that drive metastasis, the hope is that basic scientists will both identify rational molecular targets for therapy and, in parallel, develop functionally linked biomarkers that can accurately identify the patients who will benefit. 4,5 In the recent report of Hockla et al, 6 our research team has identified the protease PRSS3/mesotrypsin as such a candidate therapeutic target for metastatic prostate cancer.…”

mentioning

confidence: 99%

PRSS3/mesotrypsin in prostate cancer progression: implications for translational medicine

Radisky¹

2013

Asian J Androl

View full text Add to dashboard Cite

-Omics and Cancer Biomarkers: Link to the Biological Truth or Bear the Consequences

Cited by 19 publications

References 37 publications

Reverse Phase Protein Arrays: Mapping the Path Towards Personalized Medicine

Reverse Phase Protein Arrays: Mapping the Path Towards Personalized Medicine

Molecular Fingerprints and Biomarkers of Breast Cancer

PRSS3/mesotrypsin in prostate cancer progression: implications for translational medicine

Contact Info

Product

Resources

About